×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Immunotherapy

Angelica Welch
Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.
Danielle Bucco
The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain. 
Silas Inman
The longest response rate lasted six months.
Danielle Bucco
Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according to findings presented at the 2017 World Congress of Melanoma.
Angelica Welch
A number of patients with lung cancer have benefitted from immunotherapy agents, and researchers in the field are excited that these treatments will continue to improve the field.
David Reardon, M.D.

David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
Yania Jansen
Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.
Kim Johnson
Immunotherapy agents are promising in the treatment of cancer, but also come with some awful side effects.
Jason Harris
The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.
Danielle Bucco
David R. Gandara, M.D., discusses the latest immunotherapy advances in lung cancer, as well as the next steps toward optimizing the use of these agents.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable